Agoracom Blog Home

Posts Tagged ‘Marijuana’

Demand for #marijuana real estate ‘astronomical’ as Canada legalizes $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 10:32 AM on Wednesday, October 24th, 2018
  • Demand for marijuana facilities, including greenhouses, indoor grow-ops and warehouses will put more demand on the country’s already tight supply of industrial real estate.
  • British Columbia and Ontario combined took up more than half of the existing grow-op space, Altus said.

The rush for cannabis is on in Canada and so is finding the real estate to grow it.

The legalization of recreational weed on Wednesday has already fuelled a sixfold surge in pot-growing facilities to 8.7 million square feet (808,256 square meters) in the year through September, according to data from Altus Group Ltd. — space about the size of Amazon.com Inc.’s Seattle headquarters. Publicly listed companies have another 6.4 million square feet on the drawing board, not including retail.

“It’s grown astronomically,” Raymond Wong, vice president of data operations at Toronto-based Altus, said by phone. “With the publicly traded companies, there’s a lot more investment in these areas with anticipated growth and available capital, and they’re acquiring and expanding their existing facilities.”

The demand for marijuana facilities, including greenhouses, indoor grow-ops and warehouses will put more demand on the country’s already tight supply of industrial real estate. British Columbia and Ontario combined took up more than half of the existing grow-op space, Altus said.

Wong said expansion plans are likely conservative as it excludes private companies’ anticipated growth. “There’s a whole other market out there that anticipates further growth in this area,” he said. “We don’t see this slowing down.”

Source: https://business.financialpost.com/real-estate/property-post/demand-for-pot-grow-ops-is-astronomical-as-canada-legalizes

Tetra Bio-Pharma $TBP.ca Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:30 AM on Wednesday, October 24th, 2018

Logo tetrabiopharma rgb web

  • Announced the appointment of Richard Giguère to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.
  • Mr. Giguère has more than 20 years’ experience in national sales and marketing in the pharmaceutical industry. During his career, he has held numerous business development, management and negotiation positions and launched several new products on the Canadian market

ORLEANS, Ontario, Oct. 24, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the appointment of Richard Giguère to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.

Mr. Giguère has more than 20 years’ experience in national sales and marketing in the pharmaceutical industry. During his career, he has held numerous business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for several pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships. Over the past 10 years, he served as a member of the Board of Directors of the companies for which he worked.

“Richard has demonstrated his ability as a company builder which will prove crucial in his role as Chief Executive Officer of Tetra Natural Health,” stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc.  “He has begun preparing Tetra Natural Health as a wholly owned subsidiary of Tetra Bio-Pharma with the intentions of creating a market leader in the wellness sector of the cannabis market.”

“I am honored by this appointment as well by the confidence that Tetra Bio-Pharma has shown in me,” said Richard Giguère, CEO of Tetra Natural Health Inc. “As the CEO of Tetra Natural Health, I am excited and deeply committed to lead the operations of Tetra Natural Health with my colleagues through the next stages of development and success. Tetra has a sound business model, and there are several significant opportunities for Tetra Natural Health to grow and commercialize innovative natural health products. I am committed to exploiting the development of this huge potential market in the natural health sector.”

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

Canada Running Short Of #Marijuana After Legalization $BOG.ca $NBUD.a $MCOA $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:54 AM on Monday, October 22nd, 2018

  • Just two days after it legalized the sale and personal use of recreational marijuana on Oct. 17, Canada has found itself suffering from a shortage of the commodity
  • Canadian cannabis producers and stores apparently underestimated the huge surge in demand for cannabis following its legalization.

Oct 22, 2018 06:47 PM

The United States might be in for the same surprise when it legalizes the use of recreational marijuana or cannabis in the future.

Just two days after it legalized the sale and personal use of recreational marijuana on Oct. 17, Canada has found itself suffering from a shortage of the commodity. Canadian cannabis producers and stores apparently underestimated the huge surge in demand for cannabis following its legalization.

Under the new law, Canadian citizens will be allowed to carry up to 30 grams of cannabis in public and each household will be able to grow up to four marijuana plants.

Statistics Canada, the country’s national statistics agency, estimated that 5.4 million Canadians will buy cannabis from legal dispensaries in 2018. That’s about 15 percent of the population. In addition, some 4.9 million Canadians already smoke weed. These projections included a boost from legalization but were still off the mark due to the high demand for cannabis.

Bill Blair, who led the government’s cannabis legalization program, said the country is unable to supply enough to meet demand. He said the government expected “certain strains might run out and there would be a bit of a run on supply.”

Cannabis supply began running low on Oct. 19. The supply dearth saw retailers are turning people away because they’d run out of stock.

The Ontario Cannabis Retail Corporation, the sole legal retailer of recreational cannabis in the province of Ontario, said some cannabis items are unavailable on its website. It said given the scarcity of cannabis products across Canada, it expects “significant” short-term supply problems.

Cannabis retailers in Alberta and Prince Edward Island said certain cannabis products quickly sold out online after vigorous business on their cannabis sales websites on the first day of legalization. Experts said the supply shortage situation is the same across Canada.

Experts said the shortage of cannabis brings with it the risk Canada might soon run out of practically its entire inventory of cannabis products. The situation is due to supply and demand with many users stocking-up due to worries there might not be enough stock in the stores over the next few weeks.

Cannabis demand is under threat because supply didn’t ramp up to meet demand, said marijuana advocate Steven Stairs. He expects the government to step in and try to ensure supply by mitigating regulation and taxation.

The Cannabis Commerce Association of Canada said most of the cannabis produced in Canada right now doesn’t come from the black market but rather from medically licensed growers, or the grey market. These licensed growers weren’t able to ramp-up production in time to meet demand because weed wasn’t legal at the time so there was no sense in boosting production.

Growers also held off on planting more weed because licenses allowing them to do so weren’t available before Oct. 17. Those who applied on Oct. 17 are still waiting for their applications to be processed.

Source: http://en.businesstimes.cn/articles/104225/20181022/canada-running-short-marijuana-legalization.htm

No. 1 Wall Street #pot analyst says the #marijuana market will be much bigger than she first thought $BOG.ca $NBUD.ca $MCOA $APPB

Posted by AGORACOM-JC at 10:53 AM on Friday, October 12th, 2018
  • The cannabis industry’s rapid evolution and new strategic partnerships with mainstream brands reveal a far larger possible market for legal marijuana than investors and analysts first anticipated, according to Cowen.
  • Cowen’s Vivien Azer nearly triples her 12-month price forecast on Canadian marijuana producer Tilray this week to $172 from $62.
  • Recreational use of cannabis in Canada becomes legal Oct. 17, though each of the country’s 10 provinces will be able to regulate the market within their jurisdiction.

Wall Street’s top pot analyst says marijuana market will be much bigger than she first thought   23 Hours Ago | 00:58

With Canada about to legalize recreational use of marijuana, the industry’s rapid evolution and new strategic partnerships with mainstream brands reveal a far larger possible market for pot than investors and analysts first anticipated, according to Cowen.

“With cannabis, you’re talking about this massive step change in terms of the addressable market,” Vivien Azer said on CNBC’s “Squawk Box” on Wednesday. “You’re bringing a $7 billion illicit market into the legal market and so it does require a different valuation framework.”

Azer, the only pot analyst from a major Wall Street research house, nearly tripled her 12-month price forecast on Canadian marijuana producer Tilray this week to $172 from $62. The new target for the stock, which trades in the U.S. on the Nasdaq, implies more than 30 percent upside from current levels. She also upped her forecast on Canadian pot company Canopy Growth.

Supply remains critical issues for cannabis companies, says analyst   8:17 AM ET Wed, 10 Oct 2018 | 01:51

Just how big the market will get is tough to put a number on right now, but Azer cites a cannabis executive who estimated the market could be one day worth $500 billion.

“Our broader, big picture view of cannabis goes beyond the adult use launch in Canada,” she wrote in a report this week. “Rather, we believe this is the first step toward the establishment of cannabis as a key functional ingredient touching multiple consumer categories with four key verticals: adult use, beauty and nutraceuticals, OTC pain and sleep, and pharmaceuticals.”

Recreational use of cannabis in Canada becomes legal Oct. 17, though each of the country’s 10 provinces will be able to regulate the market within their jurisdiction independent of Ottawa.

While it’s still early days for the marijuana business, the first signs of its broader applications are easily recognized.

Tilray shares, which are up more than 650 percent since their July IPO, posted one of their best days ever mid-September after the company announced approval from the Drug Enforcement Administration to import weed to the U.S. for medical research.

In a move likely foreshadowing broader pharmaceutical application, the company will work with the University of California San Diego Center for Medicinal Cannabis Research to study the safety, tolerability and efficacy of marijuana for a neurological disorder.

“If this study can identify cannabinoids as a potential treatment for patients suffering from essential tremor, we can conduct further research and potentially provide alternative effective methods of relief for the high numbers of patients with Essential Tremor,” said Catherine Jacobson, director of clinical research at Tilray.

The globe’s major alcohol companies have also wasted no time exploring joint ventures with a handful of lucky cannabis producers.

Alcohol vs. Cannabis use in the U.S.

Constellation Brands recently increased its investment in Canopy Growth with a 9.9 percent stake in the company, granting the Corona beer brewer a foothold in an industry it expects to soon be legal in the United States.

“We think that we’re by far the best company in the world — or in the best position in the world of any company — to capitalize on what is absolutely without a doubt going to be a huge market over the next 10 years, hundreds of billions of dollars,” Constellation CEO Robert Sands said in the company’s earnings call Thursday.

“We expect to reap the benefits of our cannabis investment, which we see as being incremental to our core beer, wine and spirits portfolio,” he added.

Richard Lautens | Toronto Star | Getty Images
Dried plants are processed and trimmed by hand. A a state-of-the-art fully automated medical marijuana production facility is in a nondescript building in Scarborough.

And while the upside for Constellation appears obvious, the benefit is two-fold. A check from one of the world’s largest brewers is a welcome influx of capital for a handful of companies whose success will likely be defined by their ability to raise capital and scale production.

“Given the nascent stage of global cannabis, we believe that revenue growth should serve as the primary valuation methodology,” Cowen’s Azer said in her note. Specifically, Azer said her primary measurement when drawing price estimates is enterprise value divided by sales, divided by revenue growth, akin to a traditional price/earnings growth ratio.

Some Wall Street firms cover the pot stocks, but none the size of Cowen. It’s still an emerging industry.

To be sure, the spike in certain pot stocks — combined with a limited count of floating shares for some companies — has left stocks like Tilray and Canopy with lofty valuations and rampant volatility.

Tilray has about 93 million shares outstanding, but the float — those shares actually available for trading — is just 21 million, according to FactSet.

Tilray’s 2020 P/E ratio, meanwhile, is currently 300; Canopy’s is 125. Tilray’s stock price has posted no less than 12 days of double-digit moves on percentage basis in the last month.

“There have been no shortage of recent catalysts to spur market and investor interest,” Azer said. “As such, volatility should be seen as a natural occurrence in the cannabis market, and not dissimilar to other nascent industries.”

https://www.cnbc.com/2018/10/10/top-pot-analyst-says-weed-market-bigger-than-first-thought.html

Canada to Open More Than 100 Pot Shops as It Becomes the Second Country to Legalize Marijuana $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 2:26 PM on Thursday, October 11th, 2018

  • On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace. Uruguay launched legal sales last year, after several years of planning.
  • It’s a profound social shift promised by Canadian Prime Minister Justin Trudeau and fueled by a desire to bring the black market into a regulated, taxed system after nearly a century of prohibition.

(DELTA, British Columbia) — Mat Beren and his friends used to drive by the vast greenhouses of southern British Columbia and joke about how much weed they could grow there.

Years later, it’s no joke. The tomato and pepper plants that once filled some of those greenhouses have been replaced with a new cash crop: marijuana. Beren and other formerly illicit growers are helping cultivate it. The buyers no longer are unlawful dealers or dubious medical dispensaries; it’s the Canadian government.

On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace. Uruguay launched legal sales last year, after several years of planning.

It’s a profound social shift promised by Canadian Prime Minister Justin Trudeau and fueled by a desire to bring the black market into a regulated, taxed system after nearly a century of prohibition.

It also stands in contrast to the United States, where the federal government outlaws marijuana while most states allow medical or recreational use for people 21 and older. Canada’s national approach has allowed for unfettered industry banking, inter-province shipments of cannabis, online ordering, postal delivery and billions of dollars in investment; national prohibition in the U.S. has stifled greater industry expansion there.

Hannah Hetzer, who tracks international marijuana policy for the New York-based Drug Policy Alliance, called Canada’s move “extremely significant,” given that about 25 countries have already legalized the medical use of marijuana or decriminalized possession of small amounts of pot. A few, including Mexico, have expressed an interest in regulating recreational use.

“It’s going to change the global debate on drug policy,” she said. “There’s no other country immediately considering legalizing the nonmedical use of cannabis, but I think Canada will provide almost the permission for other countries to move forward.”

At least 109 legal pot shops are expected to open across the nation of 37 million people next Wednesday, with many more to come, according to an Associated Press survey of the provinces. For now, they’ll offer dried flower, capsules, tinctures and seeds, with sales of marijuana-infused foods and concentrates expected to begin next year.

The provinces are tasked with overseeing marijuana distribution. For some, including British Columbia and Alberta, that means buying cannabis from licensed producers, storing it in warehouses and then shipping it to retail shops and online customers. Others, like Newfoundland, are having growers ship directly to stores or through the mail.

Federal taxes will total $1 per gram or 10 percent, whichever is more. The feds will keep one-fourth of that and return the rest to the provinces, which can add their own markups. Consumers also will pay local sales taxes.

Some provinces have chosen to operate their own stores, like state-run liquor stores in the U.S., while others have OK’d private outlets. Most are letting residents grow up to four plants at home.

Canada’s most populous province, Ontario, won’t have any stores open until next April, after the new conservative government scrapped a plan for state-owned stores in favor of privately run shops. Until then, the only legal option for Ontario residents will be mail delivery — a prospect that didn’t sit well with longtime pot fan Ryan Bose, 48, a Lyft driver.

“Potheads are notoriously very impatient. When they want their weed, they want their weed,” he said after buying a half-ounce at an illicit medical marijuana dispensary in Toronto. “Waiting one or two three days for it by mail, I’m not sure how many will want to do that.”

British Columbia, home of the “B.C. Bud” long cherished by American pot connoisseurs, has had a prevalent marijuana culture since the 1970s, after U.S. draft-dodgers from the Vietnam War settled on Vancouver Island and in the province’s southeastern mountains. But a change in government last year slowed cannabis distribution plans there, too, and it will have just one store ready next Wednesday: a state-run shop in Kamloops, a few hours’ drive northeast of Vancouver. By contrast, Alberta expects to open 17 next week and 250 within a year.

No immediate crackdown is expected for the dozens of illicit-but-tolerated medical marijuana dispensaries operating in British Columbia, though officials eventually plan to close any without a license. Many are expected to apply for private retail licenses, and some have sued, saying they have a right to remain open.

British Columbia’s ministry of public safety is forming a team of 44 inspectors to root out unlawful operations, seize product and issue fines. They’ll have responsibility for a province of 4.7 million people and an area twice as large as California, where the black market still dwarfs the legal market that arrived in January.

Chris Clay, a longtime Canadian medical marijuana activist, runs Warmland Centre dispensary in an old shopping mall in Mill Bay, on Vancouver Island. He is closing the store Monday until he gets a license; he feared continuing to operate post-legalization would jeopardize his chances. Some of his eight staff members will likely have to file for unemployment benefits in the meantime.

“That will be frustrating, but overall I’m thrilled,” Clay said. “I’ve been waiting decades for this.”

The federal government has licensed 120 growers, some of them enormous. Canopy Growth, which recently received an investment of $4 billion from Constellation Brands, whose holdings include Corona beer, Robert Mondavi wines and Black Velvet whiskey, is approved for 5.6 million square feet (520,000 square meters) of production space across Canada. Its two biggest greenhouses are near the U.S. border in British Columbia.

Beren, a 23-year cannabis grower, is a Canopy consultant.

“We used to joke around all the time when we’d go to Vancouver and drive by the big greenhouses on the highway,” he said. “Like, ‘Oh man, someday. It’d be so awesome if we could grow cannabis in one of these greenhouses.’ We drive by now, and we’re like, ‘Oh, we’re here.’”

Next to Canopy’s greenhouse in Delta is another huge facility, Pure Sunfarms, a joint venture between a longtime tomato grower, Village Farms International, and a licensed medical marijuana producer, Emerald Health Therapeutics. Workers pulled out the remaining tomato plants last winter and got to work renovating the greenhouse as a marijuana farm, installing equipment that includes lights and accordion-shaped charcoal vents to control the plant’s odor. By 2020, the venture expects to move more than 165,000 pounds (75,000 kg) of bud per year.

Some longtime illegal growers who operate on a much smaller scale worry they won’t get licensed or will get steamrolled by much larger producers. Provinces can issue “micro-producer” licenses. But in British Columbia, where small-time pot growers helped sustain rural economies as the mining and forestry industries cratered, the application period hasn’t opened yet.

Sarah Campbell of the Craft Cannabis Association of BC said many small operators envision a day when they can host visitors who can tour their operations and sample the product, as wineries do.

Officials say they intend to accommodate craft growers but first need to ensure there is enough cannabis to meet demand when legalization arrives. Hiccups are inevitable, they say, and tweaks will be needed.

“Leaving it to each province to decide what’s best for their communities and their citizens is something that’s good,” said Gene Makowsky, the Saskatchewan minister who oversees the province’s Liquor and Gaming Authority. “We’ll be able to see if each law is successful or where we can do better in certain areas.”

British Columbia safety minister Mike Farnworth said he learned two primary lessons by visiting Oregon and Washington, U.S. states with recreational marijuana. One was not to look at the industry as an immediate cash cow, as it will take time to displace the black market. The other was to start with relatively strict regulations and then loosen them as needed, because it’s much harder to tighten them after the fact.

Legalization will be a process more than a date, Farnworth said.

“Oct. 17th is actually not going to look much different than it does today,” he said.

Source: http://time.com/5421443/canada-legal-marijuana-sales/

Marijuana Company of America $MCOA Applies for Uplisting to OTCQB and Finalizes S1 Registration Statement for Anticipated Equity Financing; Announces New Independent Director and Chief Financial Officer $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:00 AM on Thursday, October 11th, 2018

15233 mcoa

  • Announced that the Company filed an application with the OTC Markets on October 3, 2018, to uplist from the OTC Pink to the OTCQB listing tier on the OTC Markets
  • Additionally, the Company is in the process of finalizing a registration statement on Form S-1 that the Company intends to file with the Securities and Exchange Commission (SEC), in conjunction with an anticipated equity line of financing that will allow the Company, once the S-1 is effective, to raise up to $10 million.

Escondido, California–(October 11, 2018) – Marijuana Company of America Inc. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that the Company filed an application with the OTC Markets on October 3, 2018, to uplist from the OTC Pink to the OTCQB listing tier on the OTC Markets.

Additionally, the Company is in the process of finalizing a registration statement on Form S-1 that the Company intends to file with the Securities and Exchange Commission (SEC), in conjunction with an anticipated equity line of financing that will allow the Company, once the S-1 is effective, to raise up to $10 million. The Company’s application to uplist to the OTCQB tier is a condition for both the equity line of financing and for the Form S-1 registration statement.

Donald Steinberg, MCOA President and CEO commented: “Our goal is to obtain the necessary capital through our S1 to capitalize on the host of opportunities available in the cannabis and hemp industry right now. Also, moving to a higher OTC Markets reporting tier will help to provide better access to institutional investors, broaden our shareholder base, and provide greater credibility with the Company’s partners, clients, stakeholders, and customers, as well as with the wider investment community.”

The OTCQB tier increases transparency, reporting standards, management certification and compliance requirements. Further, the majority of broker dealers trade stocks on the OTCQB and historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.

On August 31, 2018, the Company engaged Mr. Jesus Quintero as its new Chief Financial Officer, and on September 19, 2018, appointed Robert Coale as an independent director.

Mr. Quintero has served as a financial consultant to several multi-million dollar businesses in South Florida. He has extensive experience in public company reporting and SEC/SOX compliance, and held senior finance positions with Avnet, Inc., Latin Node, Inc., Globetel Communications Corp. and Telefonica of Spain. His prior experience also includes tenure with Price Waterhouse and Deloitte & Touche. Mr. Quintero earned a B.S. in Accounting from St. John’s University and is a certified public accountant.

Mr. Coale brings years of experience in business consulting, private equity investments, financial and strategic joint venture facilitation, including telecommunications, banking, fund raising, non-profit, retirement, entertainment, licensing, gateway interface/merchant processing, real estate development, and strategic planning. Mr. Coale holds a Master’s in Business Administration, with an emphasis on International Marketing and Strategic Planning from Pepperdine University awarded in 1992; a Bachelor of Science with an emphasis in Finance from the University of Southern California awarded in 1982.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com

hempSMART.com

NetworkNewsWires/MCOA

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Food and Drug Administration #FDA confirms nonclinical and manufacturing requirements #Tetra $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:56 AM on Thursday, October 11th, 2018

Logo tetrabiopharma rgb web

  • Received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™Â mucoadhesive product
  • Meeting was held to confirm that the proposed chemistry and manufacturing and non-clinical development plan for PPP002 for the 505(b)(2) is acceptable
  • The FDA established that Tetra Bio-Pharma’s proposed bridging strategy fulfilled all the requirements of the 505(b)(2) regulatory pathway for the product PPP002

ORLEANS, Ontario, Oct. 11, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced it received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™Â mucoadhesive product.   The meeting was held to confirm that the proposed chemistry and manufacturing and non-clinical development plan for PPP002 for the 505(b)(2) is acceptable.

The FDA established that Tetra Bio-Pharma’s proposed bridging strategy fulfilled all the requirements of the 505(b)(2) regulatory pathway for the product PPP002.  The FDA also provided feedback on the chemistry and manufacturing aspects of the drug development plan.  The FDA further confirmed that the product control strategy, ensuring the identity, potency, purity and quality of the PPP002 buccal tablets was acceptable thereby determining that Tetra Bio-Pharma’s plan is on track for drug approval.

“We have now completed our meetings with the U.S. FDA and Tetra is well on its way to finalizing the development plan to bring PPP002 to market,” said Guy Chamberland, M.Sc., Ph.D., Interim Chief Executive Officer and CSO of Tetra Bio-Pharma. “With both the Type B and C meetings now behind us, we are able to move forward with executing the clinical program for PPP002 and subsequently submit the New Drug Application to commercialize PPP002.”

Tetra, along with its partner IntelGenx Corp, is developing this product in the United States under the accelerated 505(b)(2) pathway for the indication of chemotherapy-induced nausea and vomiting, and anorexia and weight loss in people with AIDS. These are the same indications that have already been approved for Marinol®.  The 505(b)(2) speciality Contract Research Organization, Camargo, is guiding the regulatory submissions to the FDA. Tetra is also developing PPP002 in Canada as an adjunct therapy for opioid reduction in patients with chronic pain.

According to the International Agency for Research on Cancer, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US $1.88 billion by 2020, an increase from its 2013 valuation of US$1.28 billion. Based on the expected improved safety profile of delayed release dronabinol, Tetra expects that AdVersa™ can gain significant market share within three years of its launch in the USA.

About Tetra Bio-Pharma Inc.

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP002, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

CLIENT FEATURE: Bougainville Ventures $BOG.ca a Turnkey Greenhouse Growing Infrastructure Provider $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 11:08 AM on Wednesday, October 10th, 2018

WHY BOUGAINVILLE?

  • Converting irrigated farmland to greenhouse-equipped farmland
  • Bougainville does not “touch the plant” by only providing agricultural infrastructure as a landlord for licensed marijuana growers
  • First 10,000 square feet (of 30,000 sqf) greenhouse space has been completed
  • Ready for occupancy
  • Room for expansion
  • Facility projected to produce in excess of 12,000 lbs. of high quality cannabis per annum upon completion of all greenhouses
  • JV Agreement with Marijuana Company of America (MCOA:OTC)
  • MCOA investment of $1M

Early estimates show a greenhouse can produce twice the amount of product and at least less than 50% of the cost compared to warehouse production.

FULL DISCLOSURE: Bougainville Ventures is an advertising client of AGORA Internet Relations Corp.

Marijuana Company of America $MCOA Appoints Ian Harvey as Global Sales Director of hempSMART(TM) in Preparation of 2019 Launch in Europe $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:19 AM on Tuesday, October 9th, 2018

15233 mcoa

  • Company has appointed Ian Harvey as the Global Sales Director of its wholly-owned UK subsidiary hempSMART™, Ltd. in preparation for the Company’s January 2019 product launch in Europe.
  • Under the guidance of Ian Harvey, hempSMART is preparing to launch its successful Network Marketing program and industrial hemp derived Cannabidiol (CBD) product line in Europe in January 2019, starting with the United Kingdom.
  • Pre-registration for the UK is available by visiting www.hempsmart.co.uk.

Escondido, California–(October 9, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that the Company has appointed Ian Harvey as the Global Sales Director of its wholly-owned UK subsidiary hempSMART™, Ltd. in preparation for the Company’s January 2019 product launch in Europe.

Under the guidance of Ian Harvey, hempSMART is preparing to launch its successful Network Marketing program and industrial hemp derived Cannabidiol (CBD) product line in Europe in January 2019, starting with the United Kingdom. Pre-registration for the UK is available by visiting www.hempsmart.co.uk.

Ian Harvey has been involved in the direct sales industry for over 35 years. Mr. Harvey has worked for and helped to develop several successful Blue Chip corporations in countries around the world including Japan, South Africa, the United States, and numerous European countries. He has several years of experience launching new product brands, training programs, and implementing strategic approaches designed to capture large networks of loyal customers on an international level.

Donald Steinberg, MCOA CEO, commented, “We are very excited to add Ian Harvey to our hempSMART team. Throughout my career I have successfully launched several companies internationally, and with Mr. Harvey’s experience and hempSMART’s incredible product formulations, I see a unique opportunity to establish and grow our brand to become a household name in Europe and eventually worldwide.”

Ian Harvey commented, “I am extremely excited to be appointed as the Global Sales Director for hempSMART. My goal is to make hempSMART a brand name recognized in households worldwide. It is a great feeling to know many lives will be transformed as we rollout out our expansion plans. Our new Regional support center based in the UK is gearing up to get ready for what is expected to be a massive success story in Europe. We have started our prelaunch in the UK with a vision of being fully launched in January. Once launched, we will then move forward with a very ambitious rollout program to include several European countries along with other Global markets.”

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

CLIENT FEATURE: Bougainville Ventures $BOG.ca a Turnkey Greenhouse Growing Infrastructure Provider $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 11:08 AM on Friday, September 28th, 2018

681747 5720 copy 2

WHY BOUGAINVILLE?

  • Converting irrigated farmland to greenhouse-equipped farmland
  • Bougainville does not “touch the plant” by only providing agricultural infrastructure as a landlord for licensed marijuana growers
  • First 10,000 square feet (of 30,000 sqf) greenhouse space has been completed
  • Ready for occupancy
  • Facility projected to produce in excess of 12,000 lbs. of high quality cannabis per annum upon completion of all greenhouses
  • JV Agreement with Marijuana Company of America (MCOA:OTC)
  • MCOA investment of $1M

Early estimates show a greenhouse can produce twice the amount of product and at least less than 50% of the cost compared to warehouse production.

FULL DISCLOSURE: Bougainville Ventures is an advertising client of AGORA Internet Relations Corp.